Generalized Myasthenia Gravis Clinical Trials in Chattanooga, Tennessee

4 studies are recruiting for generalized myasthenia gravis in Chattanooga, Tennessee right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod

   This study is part of the ADAPT Forward platform study (NCT07294170). ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis. The goal is to find the best therapeutic approach to reduce patients' side effects a…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Erlanger Health System, Chattanooga, Tennessee

   Locations

   32 in total

   Run by

   argenx

   See if you can join NCT07284420 on ClinicalTrials.gov

2. ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

   ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis. The goal is to find the best therapeutic approach to reduce patients' side effects and improve their quality of life.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Erlanger Health System, Chattanooga, Tennessee

   Locations

   35 in total

   Run by

   argenx

   See if you can join NCT07294170 on ClinicalTrials.gov

3. Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

   The purpose of this clinical study is to determine the efficacy and safety of a new oral cladribine formulation in participants with Generalized Myasthenia Gravis (gMG) in comparison to placebo. It will also investigate the sustained efficacy, the need for retreatment, and the long-term safety of o…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Erlanger Health, Inc. - 1123255, Chattanooga, Tennessee

   Locations

   153 in total

   Run by

   Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

   See if you can join NCT06463587 on ClinicalTrials.gov

4. Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)

   Long-term, multicenter, multinational, observational, registry of patients with gMG that is designed to collect data on clinical outcomes and safety in patients prescribed Alexion C5 inhibitor therapies (C5IT) such as eculizumab (Soliris®) and ravulizumab (Ultomiris®).

   Stage

   Not phased

   Ages

   18 and older

   Site

   Clinical Trial Site, Chattanooga, Tennessee

   Locations

   51 in total

   Run by

   Alexion Pharmaceuticals, Inc.

   See if you can join NCT04202341 on ClinicalTrials.gov